Milacemide

In today's article, we want to talk about Milacemide and its importance in today's society. Milacemide is a topic that has gained relevance in recent years, generating a debate worldwide. Its impact has been reflected in different aspects of daily life, from politics to popular culture. In this article, we will thoroughly explore Milacemide and analyze its influence in different areas, as well as its evolution over time. In addition, we will address the implications that Milacemide has on our society and our lives, highlighting its relevance and the need to understand it in its entirety. Don't miss this analysis that will undoubtedly give you a lot to talk about!
Milacemide
Skeletal formula of milacemide
Names
IUPAC name
N2-Pentylglycinamide
Systematic IUPAC name
2-(Pentylamino)acetamide
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
MeSH milacemide
UNII
  • InChI=1S/C7H16N2O/c1-2-3-4-5-9-6-7(8)10/h9H,2-6H2,1H3,(H2,8,10) checkY
    Key: GJNNXIYZWIZFRH-UHFFFAOYSA-N checkY
  • CCCCCNCC(N)=O
Properties
C7H16N2O
Molar mass 144.218 g·mol−1
log P 0.754
Related compounds
Related compounds
 Tricine
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).

Milacemide (INN) is an MAO-B inhibitor and glycine prodrug. It has been studied for its effects on human memory and as a potential treatment for the symptoms of Alzheimer's disease. Early clinical trials did not show positive results however, and the drug is now abandoned and it is sold as a nonprescription drug or supplement. While milacemide is not an amino-acid, it acts similarly to glycine in the brain.

References

  1. ^ "milacemide - Compound Summary". PubChem Compound. USA: National Center for Biotechnology Information. 8 August 2005. Identifiers and Related Records. Retrieved 9 January 2012.
  2. ^ "International Nonproprietary Names for Pharmaceutical Substances. Supplement to WHO Chronicle, 1983, Vol. 37, No. 6 (December). Recommended International Nonproprietary Names (Rec. INN): List 23" (PDF). World Health Organization. p. 6. Retrieved 8 January 2016.
  3. ^ a b Dysken, MW; Mendels, J; LeWitt, P; Reisberg, B; Pomara, N; Wood, J; Skare, S; Fakouhi, JD; Herting, RL (May 1992). "Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type". Journal of the American Geriatrics Society. 40 (5): 503–6. doi:10.1111/j.1532-5415.1992.tb02019.x. PMID 1634705. S2CID 34816755.
  4. ^ Harris, Carol Turkington ; foreword by Joseph R. (2002). The encyclopedia of the brain and brain disorders (2nd ed.). New York, NY: Facts on File. ISBN 0-8160-4774-X. Archived from the original on 2014-03-03. Retrieved 2017-09-10.{{cite book}}: CS1 maint: multiple names: authors list (link)
  5. ^ Theodore I. Lidsky and Jay S. Schneider Phd, Brain Candy (2001). Brain Candy. New York, United States Of America: Simon & Schuster. ISBN 9780743218436.


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Wikious
Boobota
Sagapedia